First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trialGareth J. Morgan, J. Anthony Child, Sue Bell et al.|The Lancet|2010Cited by 571
Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trialKevin J. Harrington, J. Guigay, Robert L. Ferris et al.|The Lancet Oncology|2017Cited by 431